Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system

BackgroundLecanemab and donanemab are anti-amyloid-β (Aβ) monoclonal antibodies recently approved for the treatment of Alzheimer’s disease (AD). Although both agents have demonstrated therapeutic potential, their post-marketing adverse event reporting profiles remain insufficiently characterized and...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Xiuping Feng, Shangqing Bi, Chaoqiong Shi, Qingqing Chang, Jiaming Zhang, Yiyang Zhuang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-06-01
Edice:	Frontiers in Pharmacology
Témata:	adverse events Alzheimer’s disease disproportionality analysis donanemab FAERS lecanemab
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1868789/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!